The estimated Net Worth of Aby J. Mathew is at least $10.5 Миллион dollars as of 29 May 2024. Aby Mathew owns over 517 units of Biolife Solutions Inc stock worth over $7,385,621 and over the last 10 years he sold BLFS stock worth over $1,926,983. In addition, he makes $1,211,620 as Executive Vice President and Chief Scientific Officer at Biolife Solutions Inc.
Aby has made over 85 trades of the Biolife Solutions Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 517 units of BLFS stock worth $11,260 on 29 May 2024.
The largest trade he's ever made was exercising 45,726 units of Biolife Solutions Inc stock on 12 April 2022 worth over $1,060,386. On average, Aby trades about 7,056 units every 33 days since 2014. As of 29 May 2024 he still owns at least 318,483 units of Biolife Solutions Inc stock.
You can see the complete history of Aby Mathew stock trades at the bottom of the page.
Dr. Aby J. Mathew Ph.D. serves as Executive Vice President and Chief Scientific Officer of the Company. He was Senior Vice President, Chief Technology Officer of the Company. Dr. Mathew is a co-developer of BioLife’s biopreservation media solutions and co-inventor on issued and pending patents related to methods, devices, and formulations for the preservation of cells, tissues, and organs. He holds a Ph.D. in Biological Sciences from Binghamton University and a B.S. in Microbiology from Cornell University. Dr. Mathew has been researching low temperature biopreservation since 1994, and his studies contributed to the development of BioLife’s current commercial HypoThermosol® and CryoStor® product platforms and intellectual property foundation. Dr. Mathew is currently active in, or previously a member of, AABB (formerly the American Association of Blood Banks), BEST (the Biomedical Excellence for Safer Transfusion collaborative), the International Society for Cell Therapy (ISCT), the Alliance for Regenerative Medicine (ARM), Tissue Engineering & Regenerative Medicine International Society (TERMIS), Society for Cryobiology, International Society for Biological and Environmental Repositories (ISBER), American Society for Cell Biology, and the Society for In Vitro Biology. Dr. Mathew is a member of, the Board of Directors, and Advisory Panel, of the Parent’s Guide to Cord Blood Foundation, the Scientific Advisory Board of HemaCare Corporation, the founding Board of Directors of the Cord Blood Association, the NIST-AMTech National Cell Manufacturing Consortium, the California Institute for Regenerative Medicine (CIRM) Clinical Advisory Panel, the Business Advisory Board of RoosterBio Inc., and the Scientific Advisory Board of SAVSU Technologies. Dr. Mathew has obtained UCLA Corporate Governance Program Certification.
As the Executive Vice President and Chief Scientific Officer of Biolife Solutions Inc, the total compensation of Aby Mathew at Biolife Solutions Inc is $1,211,620. There are 1 executives at Biolife Solutions Inc getting paid more, with Michael Rice having the highest compensation of $2,241,770.
Aby Mathew is 48, he's been the Executive Vice President and Chief Scientific Officer of Biolife Solutions Inc since 2019. There are 13 older and 4 younger executives at Biolife Solutions Inc. The oldest executive at Biolife Solutions Inc is Thomas Girschweiler, 61, who is the Director.
Aby's mailing address filed with the SEC is 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL, WA, 98021.
Over the last 21 years, insiders at Biolife Solutions Inc have traded over $156,215,880 worth of Biolife Solutions Inc stock and bought 12,236,637 units worth $91,960,074 . The most active insiders traders include Partners Master Fund, L.P.C..., Thomas Girschweiler и Walter Villiger. On average, Biolife Solutions Inc executives and independent directors trade stock every 13 days with the average trade being worth of $1,018,157. The most recent stock trade was executed by Sarah Aebersold on 1 July 2024, trading 3,000 units of BLFS stock currently worth $63,090.
bothell, wa-based biolife solutions, inc. (nasdaq: blfs), is a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers.
Biolife Solutions Inc executives and other stock owners filed with the SEC include: